Lupin launches Rivaroxaban for Oral Suspension 1 mg/mL in US market

Lupin announced the launch of Rivaroxaban for Oral Suspension, 1 mg/mL, in the United States. Rivaroxaban for Oral Suspension, 1 mg/mL is bioequivalent to Xarelto for Oral Suspension, 1 mg/mL of Janssen Pharmaceuticals, Inc.

Rivaroxaban for Oral Suspension is indicated for:

Treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years after at least 5 days of initial parenteral anticoagulant treatment.

Treatment of thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure.

Rivaroxaban for Oral Suspension, 1 mg/mL (RLD Xarelto) had estimated annual sales of USD 11 million in the U.S. (IQVIA MAT July 2025).

 

Powered by Capital Market - Live News